The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis by Naz, Sophia M et al.
ARTHRITIS & RHEUMATISM
Vol. 58, No. 4, April 2008, pp 985–989
DOI 10.1002/art.23402
© 2008, American College of Rheumatology
The Influence of Age at Symptom Onset and Length of
Followup on Mortality in Patients With
Recent-Onset Inflammatory Polyarthritis
Sophia M. Naz,
1 Tracey M. Farragher,
2 Diane K. Bunn,
3 Deborah P. M. Symmons,
2
and Ian N. Bruce
2
Objective. To investigate the influence of age at
symptom onset and length of followup on mortality in
patients with recent-onset inflammatory polyarthritis
(IP), and to examine predictors of mortality in relation
to disease duration.
Methods. From 1990 to 1994, patients with recent-
onset IP were registered with the Norfolk Arthritis
Register (NOAR) and followed up prospectively. Stan-
dardized mortality ratios (SMRs) were calculated for
all-cause and cardiovascular disease (CVD) mortality
and for those who were younger than age 55 years at
disease onset and for the first 5 and 10 years of followup.
Cox proportional hazards models were developed to
assess predictors of early and later mortality.
Results. Of 1,098 patients, 224 (20%) had died by
the end of 2004. All-cause and CVD mortality were
increased in rheumatoid factor (RF)–positive patients
and in this subgroup, CVD mortality was increased at
both early and later followup (SMR 5-year followup 1.93
[95% confidence interval 1.08–3.19]; SMR 10-year fol-
lowup 2.00 [95% confidence interval 1.37–2.80]). CVD
mortality was highest in seropositive patients <55 years
of age at disease onset (SMR 5.58 [95% confidence
interval 2.24–11.50]). In multivariate models, age at
onset, male sex, RF positivity, Health Assessment Ques-
tionnaire score >1.5, and nodules were predictors of
early and later mortality.
Conclusion. Patients with IP had higher rates of
CVD mortality throughout the followup period studied,
and this was highest in seropositive patients who were
<55 years of age at symptom onset. This subgroup
deserves particular attention in terms of disease and
risk factor modification. Nodules were independent
predictors of CVD mortality, suggesting that
extraarticular/vascular inflammation identifies patients
at particularly high CVD risk.
Rheumatoid arthritis (RA) is associated with
premature mortality. The excess mortality risk is highest
in patients with established disease duration of 5 years
(1). Three recent studies of early RA showed no increase
in mortality (2–4). Cardiovascular disease (CVD) mor-
tality is particularly increased in RA (5–8) and there is
evidence that excess CVD mortality begins early, espe-
cially in rheumatoid factor (RF)–positive patients (5–8).
Solomon et al also recently reported that the highest
relative risk of CVD mortality was in young RA patients
(50 years of age), while the highest absolute excess risk
was in those 75 years of age (9). However, they did not
examine all-cause mortality or the specific effect of age
at onset.
Using the Norfolk Arthritis Register (NOAR),
we tested the hypotheses that age at onset of IP and
disease duration influence all-cause and CVD mortality.
We also compared the predictors of mortality in early
versus more established disease.
PATIENTS AND METHODS
The Norfolk Arthritis Register. Briefly, the NOAR is a
primary care–based inception cohort of patients with early IP.
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985The registry covers the area of the former Norwich Health
Authority, with a population of 500,000. Primary care pro-
viders notified the NOAR of patients who were age 16 years or
older at symptom onset, had swelling of at least 2 joints that
had persisted for at least 4 weeks, and had symptom onset after
January 1, 1989. A parallel notification system operated from
hospitals within the catchment area (7,10). Between 1990 and
1994, 1,098 patients with recent-onset IP were registered with
the NOAR.
Baseline data. At baseline, a research nurse performed
a structured interview and clinical examination. Demographic
and clinical parameters, including the number of swollen and
tender joints (range 0–51), duration of morning stiffness, and
the presence of rheumatoid nodules, were recorded. A blood
sample was obtained for RF testing (latex agglutination tech-
nique). RF was considered positive at a titer of 1:40. Patients
completed a Health Assessment Questionnaire (HAQ), mod-
ified for use in British patients (11). Patients were required to
meet the 1987 American College of Rheumatology (ACR;
formerly, the American Rheumatism Association) criteria for
RA (12).
Notification and cause of death. All patients were
flagged with the Office for National Statistics (ONS) and
followed up from the date of symptom onset to December 31,
2004. Patients who left the UK (n  4; 0.36%) were censored
on the date of “embarkation.” Causes of death were coded by
the ONS from death certificate data, using the International
Classification of Diseases, Ninth Revision (ICD-9) until De-
cember 31, 2000, and the International Statistical Classification
of Diseases and Related Health Problems, Tenth Revision
(ICD-10) from January 1, 2001 onward (13). For this study,
deaths were attributed to CVD if CVD (chapter 7 in ICD-9 or
chapter I in ICD-10) was mentioned anywhere on the death
certificate.
Statistical analysis. Standardized mortality ratios
(SMRs). Age- and sex-specific mortality rates in the Norfolk
population for the years 1990–2003 were provided by the ONS
and were used to calculate the expected numbers of deaths in
the NOAR cohort. Observed and expected numbers of deaths
(all-cause and CVD, specifically) were compared using SMRs
(with 95% confidence intervals [95% CIs]), which were calcu-
lated for all patients with IP, then separately for men and
women. We also stratified patients according to whether they
satisfied the ACR 1987 classification criteria for RA at base-
line, and according to RF status at baseline.
We first examined mortality rates for patients who
were 55 years of age at IP symptom onset and those who
were 65 years of age at onset of IP. We also examined
mortality rates for both the first 5 years of followup and the
first 10 years of followup.
Predictors of mortality. Potential baseline predictors of
mortality for the whole cohort were initially assessed univari-
Table 1. SMRs in patients with inflammatory polyarthritis, by sex, length of followup, RA and RF status, and age at symptom onset*
All-cause mortality CVD mortality
Observed Expected SMR (95% CI) Observed Expected SMR (95% CI)
Sex
Both sexes 224 211.3 1.06 (0.93–1.21) 92 73.4 1.25 (1.01–1.54)
Female 115 117.5 0.98 (0.81–1.17) 46 39.3 1.16 (0.86–1.56)
Male 109 94.0 1.16 (0.95–1.40) 46 34.1 1.35 (0.99–1.80)
Length of followup
5 years 86 91.3 0.94 (0.75–1.16) 35 29.5 1.19 (0.83–1.65)
10 years 187 186.9 1.00 (0.86–1.15) 77 64.1 1.20 (0.95–1.50)
Satisfied ACR criteria for RA at baseline
Yes 123 113.1 1.09 (0.90–1.30) 44 37.8 1.17 (0.85–1.56)
No 101 98.4 1.03 (0.84–1.25) 48 35.7 1.34 (0.99–1.78)
RF status at baseline
Positive 78 55.7 1.40 (1.11–1.75) 38 19.0 2.00 (1.41–2.74)
Negative 114 129.6 0.88 (0.73–1.06) 43 46.6 0.92 (0.67–1.24)
RF status at baseline: findings at
5-year followup
Positive 33 23.8 1.39 (0.96–1.95) 15 7.8 1.93 (1.08–3.19)
Negative 42 53.3 0.79 (0.57–1.07) 16 17.8 0.90 (0.51–1.46)
RF status at baseline: findings at
10-year followup
Positive 63 49.2 1.28 (0.98–1.64) 33 16.5 2.00 (1.37–2.80)
Negative 94 113.4 0.83 (0.67–1.01) 33 40.4 0.82 (0.56–1.15)
Age at symptom onset
Entire cohort
55 years 20 18.9 1.06 (0.64–1.63) 9 5.1 1.75 (0.80–3.32)
55 years 204 192.6 1.06 (0.92–1.22) 83 68.3 1.21 (0.97–1.51)
RF-positive patients
55 years 11 4.38 2.51 (1.25–4.48) 7 1.3 5.58 (2.24–11.50)
55 years 67 51.4 1.30 (1.01–1.66) 31 17.7 1.75 (1.19–2.48)
* SMRs  standardized mortality ratios; RA  rheumatoid arthritis; RF  rheumatoid factor; 95% CI  95% confidence interval; CVD 
cardiovascular disease; ACR  American College of Rheumatology.
986 NAZ ET ALately using Cox proportional hazards regression. Baseline
predictor variables that were significant at P  0.20 on
univariate analysis were entered into a multivariate model,
which was simplified using the likelihood ratio test. Variables
that were significant at P  0.10 on multivariate analysis were
retained. Previously excluded variables (P  0.20) were added
back into the model and those that were significant at P  0.10
were retained. The proportional hazards assumption of the
final multivariate model was checked (7). All statistical analy-
ses were conducted with Stata software, release 9 (StataCorp,
College Station, TX).
RESULTS
We studied 1,098 patients, of whom 715 (65%)
were women. The median age at symptom onset was 54
years (interquartile range [IQR] 41–67) and the median
delay from symptom onset to registration was 5 months
(IQR 2–10). At baseline, 499 patients (45%) met the
ACR criteria for RA. RF was measured in 958 patients,
of whom 267 (27.9%) were RF positive. The median
followup time was 11.4 years (IQR 10–12.75). By De-
cember 31, 2004, 224 patients (20%; 115 women and 109
men) had died. CVD was the most common cause of
death (46 women [40%] and 46 men [42%]). Cancer was
the second most common cause of death (28 women
[24%] and 36 men [33%]).
In the entire cohort, all-cause mortality was not
increased (SMR 1.06 [95% CI 0.93–1.21]), but there was
a significant increase in CVD mortality (SMR 1.25 [95%
CI 1.01–1.54]) (Table 1). All-cause and CVD mortality
were not increased in those who satisfied the ACR
criteria for RA at baseline or in those with a longer
length of followup (Table 1).
All-cause mortality was significantly increased in
RF-positive patients (SMR 1.40 [95% CI 1.11–1.75]), as
was CVD mortality (SMR 2.00 [95% CI 1.41–2.74]).
This excess CVD mortality was already apparent 5 years
after symptom onset and persisted through 10 years of
followup (Table 1). In RF-positive patients, the risk of
death from all causes, and especially from CVD, was
higher in those younger than age 55 years at symptom
onset (SMR for death from all causes 2.51 [95% CI
1.25–4.48]; SMR for CVD mortality 5.58 [95% CI
2.24–11.50]). The number of excess deaths (observed
deaths minus expected deaths) was higher for RF-
positive patients age 55 years or older at symptom onset,
both for all causes (15.6 deaths for age 55 years and 6.6
for age 55 years) and for CVD (13.3 for age 55 years
and 5.7 for age 55 years). RF-positive women younger
than age 55 years at disease onset had the highest SMR
for CVD (6.13 [95% CI 1.26–17.92]).
Table 2. Baseline variables and predictors of all-cause and CVD mortality, by length of followup*
Variable
Entire IP cohort
(n  1,098)
HR (95% CI)
5-year followup 10-year followup
All-cause
mortality CVD mortality
All-cause
mortality CVD mortality
Age at symptom onset (10-year intervals),
median (IQR)
54 (41–67) 2.73 (2.26–3.28) 3.50 (2.64–4.64) 2.59 (2.29–2.95) 2.87 (2.39–3.45)
Male, no. (%) 383 (35) 2.81 (1.84–4.28) 2.30 (1.32–3.98) 2.16 (1.62–2.87) 2.25 (1.54–3.29)
Smoking status, no. (%)
Never smoked 353 (32) 1.0 1.0 1.0 1.0
Ex-smokers who stopped 15 years prior
to registration
209 (19.0) 2.06 (1.16–3.65) 2.40 (1.13–5.08) 1.40 (0.94–2.09) 1.62 (0.94–2.77)
Ex-smokers who stopped 15 years prior
to registration
237 (21.6) 1.54 (0.85–2.79) 1.41 (0.62–3.19) 1.13 (0.76–1.70) 1.31 (0.76–2.26)
Current smokers 290 (26.4) 1.19 (0.65–2.16) 1.44 (0.52–3.97) 1.14 (0.77–1.51) 1.41 (0.76–2.62)
Delay to presentation in months (tertiles),
no. (%)
Group 1 (0–2.9 months) 366 (33.3) 1.00 1.00 1.00 1.00
Group 2 (3.0–7.9 months) 368 (33.5) 0.50 (0.30–0.85) 0.33 (0.16–0.72) 0.87 (0.62–1.21) 0.73 (0.46–1.14)
Group 3 (8.0–54.0 months) 364 (33.1) 0.56 (0.34–0.93) 0.57 (0.30–1.07) 0.63 (0.44–0.92) 0.60 (0.37–0.97)
RF positive at baseline, no. (%) 267 (27.9) 2.09 (1.34–3.27) 2.41 (1.34–4.34) 1.85 (1.35–2.53) 2.43 (1.61–3.67)
Nodules present at baseline, no. (%) 73 (6.6) 2.70 (1.53–4.78) 2.16 (0.92–5.07) 2.19 (1.43–3.37) 1.95 (1.05–3.64)
Satisfied ACR criteria at baseline, no. (%) 499 (45) 1.00 (0.66–1.52) 0.68 (0.38–1.21) 1.36 (1.02–1.80) 1.30 (0.89–1.91)
HAQ score at baseline, no. (%)
1.5 832 (76.6) 1.00 1.00 1.00 1.00
1.5 254 (23.4) 1.80 (1.39–2.34) 1.94 (1.30–2.91) 1.80 (1.50–2.16) 1.70 (1.33–2.18)
*I P inflammatory polyarthritis; HR  hazard ratio; IQR  interquartile range; HAQ  Health Assessment Questionnaire (see Table 1 for other
definitions).
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age at symptom onset and sex were significant predictors
of all-cause and CVD mortality at both early and later
followup (Table 2). Patients who presented late (8
months from symptom onset) were less likely to die
during followup than those who presented earlier (haz-
ard ratio [HR] 0.56 [95% CI 0.34–0.93]). There was an
unexpected relationship between smoking and mortality.
Compared with never smokers, ex-smokers who stopped
15 years prior to baseline had a higher mortality risk
(HR 2.06 [95% CI 1.16–3.65]). This was not seen for
ex-smokers who stopped 15 years prior to registration
(HR 1.54 [95% CI 0.85–2.79]). Nodules and RF positiv-
ity were both strong predictors of early CVD mortality
(HR 2.16 [95% CI 0.92–5.07] and HR 2.41 [95% CI
1.34–4.34], respectively) and later CVD mortality (HR
1.95 [95% CI 1.05–3.64] and HR 2.43 [95% CI 1.61–
3.67], respectively). The presence of nodules also pre-
dicted early and later all-cause mortality.
In multivariate analysis, older age at symptom
onset, male sex, and RF positivity were consistent pre-
dictors of all-cause and CVD mortality in both followup
periods (Table 3). A high baseline HAQ score also
predicted later all-cause mortality. Interestingly, nodules
remained a significant predictor of mortality (all-cause,
HR 2.12 [95% CI 1.33–3.37] and CVD, HR 2.28 [95%
CI 1.17–4.46]), independent of RF status.
DISCUSSION
Using this primary care–based early IP cohort,
we found that excess all-cause and CVD mortality was
confined to patients who were RF positive at baseline.
Excess CVD mortality was already apparent within 5
years of symptom onset, and the highest SMR for CVD
deaths was in RF-positive women younger than age 55
years at symptom onset (SMR 6.13 [95% CI 1.26–
17.92]).
The low number of deaths in patients who were
younger at symptom onset precluded further analysis.
We found that patients older than age 55 years at
symptom onset had a higher rate of excess all-cause and
CVD deaths. This is consistent with the observations of
Solomon et al (9). Numerically, therefore, in an RA
population the majority of CVD-related deaths will still
be seen in those patients who were older at symptom
onset. While one would expect the SMR to drop with
increasing length of followup, in this study CVD mor-
tality in the RF-positive cohort remained high, even at
10 years of followup. This suggests that exposure to
chronic inflammation throughout the disease course
carries an excess risk of CVD death.
The 2 strongest independent disease-associated
predictors of CVD mortality were RF status and the
presence of nodules. Interestingly, nodules remained in
our models independent of the effect of RF status.
RF-positive patients tend to have more progressive and
severe disease with reduced physical function, all of
which may contribute to increased mortality at younger
ages, particularly from CVD. In addition, the presence
of nodules may reflect a different stage in RA patho-
genesis. Patients with nodules generally have more se-
vere extraarticular manifestations, and this inflam-
mation in the “vascular” compartment may accelerate
atherogenesis further and contribute to plaque instabil-
ity and a higher event rate. Patients with extraarticular
disease in general may also have even fewer functional
Table 3. Multivariate predictors of all-cause and CVD mortality, by length of followup*
Variable
HR (95% CI)
5-year followup 10-year followup
All-cause
mortality CVD mortality
All-cause
mortality CVD mortality
Age at symptom onset (10-year intervals) 2.71 (2.17–3.39) 3.89 (2.77–5.46) 2.50 (2.15–2.91) 2.94 (2.37–4.46)
Sex 2.28 (1.44–3.60) 1.64 (0.89–3.00) 2.19 (1.59–3.02) 2.08 (1.38–3.16)
Delay to presentation in months (tertiles)
Group 1 (0–2.9 months) 1.00 † † †
Group 2 (3.0–7.9 months) 0.52 (0.30–0.92) † † †
Group 3 (8.0–54.0 months) 0.92 (0.53–1.60) † † †
RF-positive at baseline 1.59 (1.01–2.51) 2.95 (1.58–5.50) 1.45 (1.01–2.05) 1.99 (1.31–3.01)
Nodules present at baseline 2.19 (1.18–4.05) 2.46 (0.91–6.71) 2.12 (1.33–3.37) 2.28 (1.17–4.46)
HAQ score at baseline 1.5 1.17 (0.87–1.60) † 1.29 (1.03–1.62) †
*H R hazard ratio; HAQ  Health Assessment Questionnaire (see Table 1 for other definitions).
† Baseline variable subsequently shown to not be a predictor in the multivariate model.
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Wolfe et al (14) found the HAQ score to be the most
significant predictor of mortality, and found that labo-
ratory, radiographic, and physical examination data were
substantially weaker in predicting mortality. We found
that a HAQ score of 1.5 was an independent predictor
of mortality from all causes at 10 years of followup. This
could be because it is a marker of cumulative inflamma-
tion and joint damage. Earlier in the disease course,
baseline markers of disease severity, such as RF status
and the presence of nodules, may be better indicators of
the degree of inflammation and disability.
Smoking was the only traditional CV risk factor
examined in this cohort. It was not found to be a
significant predictor of mortality. However, there were
trends toward associations of past smoking with mortal-
ity outcomes. In the context of IP, smoking may influ-
ence mortality via its effect on RF status and nodule
formation. In this cohort, 35% of the RF-positive indi-
viduals were smokers and 41% were ex-smokers.
Strengths of this study include the complete
followup, via the ONS, of a large primary care–based
inception cohort over a substantial time period. It is the
first study to examine the impact of age at disease onset
on both all-cause and CVD mortality. Although basing
the cause of death on death certificate data may lead to
misclassification, the degree of misclassification is likely
to be similar in both the IP and the general population,
and therefore would not bias the mortality risk. The
main limitation of this study is that we were unable to
examine the influence of other classic CVD risk factors.
In conclusion, in the NOAR cohort we found that
excess all-cause and CVD mortality was confined to
RF-positive patients. Excess CVD mortality was already
apparent within 5 years of symptom onset, and the
highest SMR for CVD death was seen in RF-positive
women who were younger than age 55 years at symptom
onset. However, older patients had a higher number of
excess deaths from CVD. Among our IP patients, older
age at symptom onset, male sex, RF positivity, and
presence of nodules all predicted CVD mortality.
Extraarticular/vascular inflammation may contribute to
CVD mortality over and above the influence of RF
status alone. These results suggest that primary CVD
prevention and aggressive management of inflammation
are important from the time of presentation with IP in
patients of all ages.
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